Form 8-K - Current report:
SEC Accession No. 0001171843-25-004211
Filing Date
2025-06-30
Accepted
2025-06-30 07:15:28
Documents
14
Period of Report
2025-06-30
Items
Item 7.01: Regulation FD Disclosure
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 FORM 8-K f8k_062925.htm   iXBRL 8-K 15375
2 PRESS RELEASE exh_991.htm EX-99.1 13197
  Complete submission text file 0001171843-25-004211.txt   231495

Data Files

Seq Description Document Type Size
3 XBRL SCHEMA FILE gnw-20250101.xsd EX-101.SCH 3402
4 XBRL DEFINITION FILE gnw-20250101_def.xml EX-101.DEF 26066
5 XBRL LABEL FILE gnw-20250101_lab.xml EX-101.LAB 35956
6 XBRL PRESENTATION FILE gnw-20250101_pre.xml EX-101.PRE 24702
16 EXTRACTED XBRL INSTANCE DOCUMENT f8k_062925_htm.xml XML 3334
Mailing Address 6801 N CAPITAL OF TEXAS HIGHWAY BUILDING 1; SUITE 300 AUSTIN TX 78731
Business Address 6801 N CAPITAL OF TEXAS HIGHWAY BUILDING 1; SUITE 300 AUSTIN TX 78731 512-501-2444
CASSAVA SCIENCES INC (Filer) CIK: 0001069530 (see all company filings)

EIN.: 911911336 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-41905 | Film No.: 251088743
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)